Safety of an extended-release injectable 10% moxidectin suspension
The safety of an extended-release injectable suspension of 10% moxidectin was evaluated in four studies using Beagle dogs and one study using ivermectin-sensitive Collies at a recommended dose is 0.5 mg/kg subcutaneously once yearly.
In study 1: slight swelling was detectable at some of the 3 and 5 times recommended dose.
Studies 2 and 3 showed no ill effects identified in reproductive (females) or semen quality characteristics (males).
Study 4: Showed no adverse effects.
Study 5: there were no abnormal clinical signs at the recommended dose and also at 3 and 5 times the recommended dose in ivermectin-sensitive dogs.
Read more by clicking on the link below: